CN Patent

CN109985241B — Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用

Assigned to Guangzhou Virotech Pharmaceutical Co Ltd · Expires 2024-10-18 · 2y expired

What this patent protects

本发明属于生物医药领域，涉及CDK(cyclin‑dependent kinase，周期蛋白依赖性激酶)抑制剂和溶瘤病毒在制备抗肿瘤药物的应用。本发明首次发现CDK抑制剂可以用于制备溶瘤病毒抗肿瘤增效剂。发明同时涉及一种包含CDK抑制剂以及溶瘤病毒的药物组合物，包含CDK抑制剂及溶瘤病毒的药品套装，以及CDK抑制剂与溶瘤病毒在治疗肿瘤，特别是对所述溶瘤病毒不敏感的肿瘤中的用途。

USPTO Abstract

本发明属于生物医药领域，涉及CDK(cyclin‑dependent kinase，周期蛋白依赖性激酶)抑制剂和溶瘤病毒在制备抗肿瘤药物的应用。本发明首次发现CDK抑制剂可以用于制备溶瘤病毒抗肿瘤增效剂。发明同时涉及一种包含CDK抑制剂以及溶瘤病毒的药物组合物，包含CDK抑制剂及溶瘤病毒的药品套装，以及CDK抑制剂与溶瘤病毒在治疗肿瘤，特别是对所述溶瘤病毒不敏感的肿瘤中的用途。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN109985241B
Jurisdiction: CN
Classification: —
Expires: 2024-10-18
Drug substance claim: No
Drug product claim: No
Assignee: Guangzhou Virotech Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.